This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Medivir Past Earnings Performance

Past criteria checks 0/6

Medivir has been growing earnings at an average annual rate of 41.9%, while the Biotechs industry saw earnings growing at 33.1% annually. Revenues have been declining at an average rate of 7.8% per year.

Key information

41.95%

Earnings growth rate

56.71%

EPS growth rate

Biotechs Industry Growth	17.04%
Revenue growth rate	-7.75%
Return on equity	-43.11%
Net Margin	-1,740.13%
Next Earnings Update	18 Aug 2023

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown

How Medivir makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

OTCPK:MVRB.F Revenue, expenses and earnings (SEK Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
31 Mar 23	4	-75	21	0
31 Dec 22	4	-89	21	0
30 Sep 22	16	-95	22	0
30 Jun 22	15	-94	22	0
31 Mar 22	16	-88	22	0
31 Dec 21	32	-63	21	0
30 Sep 21	12	-50	22	0
30 Jun 21	27	-32	22	0
31 Mar 21	31	-27	23	0
31 Dec 20	20	-43	25	0
30 Sep 20	30	-64	27	0
30 Jun 20	14	-91	27	0
31 Mar 20	14	-91	27	0
31 Dec 19	9	-123	35	0
30 Sep 19	21	-206	86	0
30 Jun 19	23	-254	102	0
31 Mar 19	21	-333	123	0
31 Dec 18	24	-350	132	0
30 Sep 18	15	-339	177	0
30 Jun 18	17	-348	243	0
31 Mar 18	23	-348	319	0
31 Dec 17	37	-360	392	0
30 Sep 17	42	-379	425	0
30 Jun 17	63	-353	416	0
31 Mar 17	90	-320	412	0
31 Dec 16	93	-295	400	0
30 Sep 16	-16	-262	244	70
30 Jun 16	70	-218	206	141

Quality Earnings: MVRB.F is currently unprofitable.

Growing Profit Margin: MVRB.F is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: MVRB.F is unprofitable, but has reduced losses over the past 5 years at a rate of 41.9% per year.

Accelerating Growth: Unable to compare MVRB.F's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MVRB.F is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-5.4%).

Return on Equity

High ROE: MVRB.F has a negative Return on Equity (-43.11%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2023/05/01 15:49
End of Day Share Price	2023/02/01 00:00
Earnings	2023/03/31
Annual Earnings	2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Medivir AB (publ) is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Kristofer Liljeberg-Svensson	Carnegie Investment Bank AB
Mattias Häggblom	Danske Bank
Klas Palin	DNB Carnegie Commissioned Research